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Abstract  
 
Background: Urinary tract infections (UTIs) are commonly reported by people with multiple 
sclerosis (PwMS) and have a significant impact on quality of life.  
Objective: To provide an overview of the problem of UTIs in PwMS and offer a practical 
approach for the diagnosis and management. 
Methods: A review of the literature through a Pubmed search up to October 2015 was 
performed using the following keywords: multiple sclerosis, neurogenic bladder, urinary tract 
infections, relapse, dipsticks, culture, recurrent, prevention. 
Results: Consensus now define symptomatic UTI by a positive urine culture defined by 
>105colony forming units (CFU)/mL or >104CFU/mL if a urethral catheter urine sample is 
taken, or any count of bacteria in a suprapubic bladder puncture specimen, both in addition to 
symptoms including fever, pain, changes in lower urinary tract symptoms or neurological 
status. Urinalysis is useful to exclude a UTI (negative predictive value 95%) however on its 
own is insufficient to confirm a UTI, for which urine culture is required. Experts advise 
Asymptomatic UTIs should not be treated except in the context of an acute relapse. Currently, 
from international guidelines there is no validated stategy to prevent recurrent UTIs in PwMS. 
Conclusion: This review provides an overview of the diagnosis, treatment and prevention of 
UTIs in the setting of MS.  
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Introduction 
 
Urinary tract infections  (UTIs) commonly occur in multiple sclerosis (MS).  Though a figure 
of 30% is often cited, estimates vary between 13 to 80% per patient life and this may be put 
down to the different patient cohorts studied [1]. However this is also likely to reflect the lack 
of a consensus definition or diagnostic criteria for a UTI in patients with neurological 
disorders such as MS [1].  In general, the likelihood of infection is greater with longer disease 
duration and higher EDSS score [2],[3], though UTIs may occur at any time point during the 
course of the disease [1]. Urinary tract infections may exacerbate MS-related lower urinary 
tract (LUT) symptoms such as urinary urgency, frequency and incontinence.  
Urinary tract infections are ranked amongst the top three reasons for hospitalization, being 
responsible for  30-50% of all in-patient admissions of PwMS [4],[5]. A recent audit across a 
London region estimated annual costs above £800,000   and was driven by a relatively small 
number of PwMS with frequent admissions. A prospective study of 73 patients with relapse-
remitting MS demonstrated an increased risk of exacerbation around the time of infections, 
particularly UTI [6] and that infection-related relapses were associated with  more sustained 
neurological deficits and worse quality of life compared to exacerbations not associated with 
infections, due to the burden of frequent hospitalizations and worsened LUT symptoms 
[6],[7]. There is also evidence to suggest that UTIs were a significant predictive factor for 
death in MS [3] and a retrospective analysis of a large validated UK primary care database [3] 
found that survival in MS was influenced not only by the underlying disease, but also by other  
comorbidities such as UTIs,  as well as other infections,  heart disease and cancer, and 
lifestyle factors such as smoking and alcohol abuse.   
Despite the burden of this problem, there is relatively little guidance around the evaluation 
and management of UTIs in PwMS [1],[7],[8].  So we provided an overview of the problem 
of UTI in MS by reviewing the existing evidence on the subject. Based on this review of the 
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literature and on our practice in a centre of excellence, we offered a practical approach for the 
diagnosis, treatment and prevention of UTIs in PwMS. 
 
 
Diagnosis of UTI 
 
 
Symptoms of UTI 
 
Recognising UTI in PwMS can be difficult since PwMS suffering from UTI may not report 
the symptoms typically associated such as fever, rigor, suprapubic or flank pain, urinary 
urgency, frequency or worsening urinary incontinence and haematuria.. Conversely, 
symptoms that my trigger suspicion of UTI in the general population, such as urinary 
urgency, frequency and incontinence may reflect chronic LUT dysfunction in PwMS and not 
signify infection [9].   
A UTI may need to be suspected in the presence of vague non-specific symptoms such as 
back or abdominal discomfort, reduced appetite or lethargy, deterioration of neurological 
status, leakage between intermittent self-catheterisation (ISC), catheter blockage or the report 
of a cloudy urine with increased odour [10]. These symptoms are highly sensitive (77-95%) 
for a UTI, however have low specificity (<50%) [11].    
 
Urinalysis 
 
Urinalysis (urine dipstick test), provides a rapid method of screening for UTIs. The test for 
leukocyte esterase detects the presence of azurophilic granules of monocytes and granulocytes 
(neutrophilic, eosinophilic and basophilic) whereas  the test for nitrites is a rapid screening 
method for possible infections caused by nitrate-reducing bacteria such as Escherichia coli, 
Enterobacter, Klebsiella, Citrobacter and Proteus. 
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The presence of nitrites in the urine has a sensitivity of 45-60% and specificity of 85-98% for 
a UTI, leukocyte esterase test positivity a sensitivity of 48-86% and specificity of 17-93% , 
and combined nitrites and leukocyte esterase test positivity (with one or both showing a 
positive result)   a sensitivity of 75-92% and specificity of 65-87% depending on the study 
population and independently of the method of urine collection, as reported by a metaanalysis 
which included general population, children, pregnant women, elderly patients, urological 
patients and surgical patients and patients with spinal diseases [12]. However specific data 
regarding to MS population are lacking. 
There are limitations to the use of urine dipsticks. Leukocyte esterase activity is not specific 
for a UTI and may be positive (and nitrites negative), in patients using a urinary catheter in 
the absence of UTI, or in patients already using antibiotics. Other causes of isolated 
leukocyturia (define here?) include balanitis, urethritis, tuberculosis, bladder tumours, viral 
infections, nephrolithiasis, foreign bodies, exercise, glomerulonephritis, and corticosteroid 
and cyclophosphamide use.  On the other hand, not all bacteria reduce nitrates in the urine to 
nitrites, and relying on urinalysis alone may miss infections due to Enterococcus.   
In a meta-analysis of 70 studies evaluating the diagnostic accuracy of urinalysis, Devillé et al. 
concluded that testing with urinalysis was useful to exclude  UTI in all groups including 
neurological patients, if the results for nitrites or leukocyte esterase testing were negative 
[12]. Indeed, a negative predictive value of 95%, was reported when the combined nitrite and 
leukocyte esterase test was measured against culture [13]. 
Therefore, urinalysis for the presence of nitrites and leukocyte esterase is   useful to rule out 
an infection (negative predictive value 95%). However, since the negative predictive value is 
not as 100%, it is advisable to send a urine culture if there is a high clinical suspicion for a 
UTI such as malodourous or turbid urine, despite a negative dipstick. 
 6 
 Urinalysis has a relatively low ability to diagnose an infection (positive predictive value 
<76%), thus, if urinalysis is positive, this should be followed up with urine culture to confirm 
whether indeed an infection is present. Figure 1 gives a suggested algorithm.  
 
 
Urine culture  
 
 
The gold standard for UTI diagnosis is urine culture as recommended by international 
huidelines [8]. Urine specimens may be collected either as a clean-catch midstream sample, 
from an indwelling urethral catheter or a suprapubic aspiration from a suprapubic catheter 
[14]. Urine microscopy provides information about the cell types in the urine and the term 
leukocyturia is used when there are greater than 10 white blood cells per high-power field 
(x400) in the re-suspended sediment of a centrifuged aliquot of urine, or per mm3 in unspun 
urine [14]. Urine is routinely cultured on nutrient-dense medium and incubated over 2 days 
before it is said to be negative.    
The definition for significant bacteriuria depends upon how the urine sample is collected.  For 
a routine clean-catch midstream sample, a significant growth of bacteria is defined by counts 
of >105 colony forming units (CFU)/mL [16]. For a urethral catheter urine sample, >104 
CFU/mL may be considered relevant [16] whereas for a suprapubic bladder puncture 
specimen, any count of bacteria is relevant [16].   
Escherichia coli is the most common isolated pathogen (50%), followed by Pseudomonas 
aeruginosa (15%), Acinetobacter (15%), Enterococcus faecalis (6%) and multiorganismic 
infections [17],[18]. This is in contrast to the pathogens cultured in simple UTIs which are 
Escherichia coli (90%), Proteus (5%) and Klebsiella (4%) [16]. Organisms such as Chlamydia 
and Ureaplasma urealyticum should be considered in patients with leukocyturia and negative 
routine cultures. 
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Patients using catheters may often consistently have uropathogens cultured form their urine  
(known as asymptomatic bacteriuria) [16] and therefore, periodically sending urine samples 
for culture should be discouraged in the absence of fresh neurological or urological 
symptoms.  
Positive urine culture should be followed by identification of sensitivities to antibiotics in 
order to decide treatment. By definition, a multiresistant microorganism cultured is resistant 
to three or more different antibiotics [19]. 
 
 
Recurrent UTIs 
 
Some PwMS  experience recurrent UTIs  and though a standard definition is lacking, 
according to the guidelines of the European Association of Urology, a patient reporting at 
least three episodes of UTIs documented by culture in the past 12 months, or two UTI 
episodes in the preceding six months is said to have recurrent UTIs [16].  Risk factors for 
recurrent UTIs have been poorly studied, however it is thought that the presence of LUT 
dysfunction such as detrusor overactivity, detrusor sphincter dyssynergia or incomplete 
bladder emptying with large post-void residual volumes, the use of urinary catheters, the 
presence of vesicoureteric reflux, female gender and the use of immunosuppressive treatment 
increases the likelihood for UTIs [2],[3],[21]. Increasing functional dependence is associated 
with greater difficulties in toileting and personal hygiene and may increase the risk for UTIs.  
Urinary retention increases the risk for UTIs [2],[8] because of the multiplication of bacteria 
due to stagnation of urine in the bladder. It is therefore recommended that patients with high 
post-void residuals should regularly perform ISC to reduce the risks for UTI [1],[8],[20]. 
However, the use of a catheter is in itself associated with a risk for developing  UTIs [21] by 
compromising the host defences in several ways. Catheterisation obviates the protection from 
 8 
infections afforded by the length of urethra between the external and internal urethral 
openings as bacteria are deposited directly into the bladder [22]. A glycosaminoglycan layer 
coats the mucosal surface of the bladder in health, and a catheter traumatises the bladder wall 
resulting in urothelial damage and compromise to this layer [23].  This increases the chances 
for bacterial penetration across the bladder wall. Mechanical cleansing of the LUT by natural 
voiding is yet another defence against infections that is compromised by an indwelling 
catheter. The biofilm that forms on the surface of the indwelling catheter creates an ideal 
environment for the growth of microorganisms and contributes to the emergence of resistance 
to host defences and antimicrobials. For this reason, intermittent cathterisation is associated 
with  a reduced risk for UTIs compared to an indwelling catheter.   Adopting a sterile 
technique (versus clean) further reduces the risk for UTI and/or bacteriuria compared with 
clean intermittent catheterisation, however this is usually not a feasible option  in routine 
practice [8].  
 
 
Management of UTIs in patients with MS 
 
Asymptomatic bacteriuria 
 
Asymptomatic bacteriuria in PwMS should not be treated (figure 1) [16] except in the context 
of an acute MS relapse [24]. Treating  asymptomatic bacteriuria is not associated with better 
outcomes, and also results in resistant bacterial strains [16]. 
 
Symptomatic UTI 
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Antibiotic treatment is recommended for symptomatic UTIs (figure 1). Empirical treatment is 
usually initiated with broad-spectrum antibiotics based on local susceptibility patterns or the 
patient’s previous microbiology results, and the choice of antibiotics may need to be adjusted 
according to the results of urine culture (figure 1). There is no recommendation in the 
literature about the duration of treatment. By definition, UTIs occurring in PwMS are 
complicated, as they are associated with structural or functional abnormalities of the 
genitourinary tract in the presence of an underlying disease and therefore the risk for failing 
therapy is greater [16]. A 5-7 day course of antibiotic treatment is generally advised, which 
may be extended to 14 days according to the severity of infection [8]. Symptomatic 
complicated UTI in the setting of an indwelling catheter should be treated with a narrow 
spectrum antibiotic whenever possible, and modified based on culture and sensitivity results 
[16].  
 
 
Suspected UTI in the patient with an MS relapse  
 
In the case of suspected UTI in the context of a relapse, corticosteroid therapy should not be 
delayed and the initiation of antibiotic treatment is influenced by the results of urinalysis. 
Rakusa et al [24] presented a urinalysis algorithm for UTI prior to initiation of corticosteroid 
therapy in PwMS who experienced relapse. In this study, the use of the urinalysis (positive if 
either leukocyte esterase or nitrites positive) had a specificity of 78% and a sensitivity of 
75%. Negative predictive value of urinalysis was 96%. Neither the 3% of patients with false 
negative urinalysis nor the 18% false positive patients who were unnecessarily treated with 
antibiotics for 48h had any clinical adverse events. PwMS with systemic features of infection 
were excluded eg fever. Mahadeva et al reported a similar result in a large audit   and also 
supported the initiation of corticosteroid treatment administered simultaneously with 
antibiotic treatment for the UTI, with the same caveats.  [25].  
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Recurrent UTIs 
Guidance for the management of recurrent UTIs is lacking. Urinary tract infections may 
exacerbate MS-related lower urinary tract (LUT) symptoms such as urinary urgency, 
frequency and incontinence and infections may also predispose to complications of the upper 
urinary tract including stones, pyelonephritis and vesicoureteric reflux [1]. 
 
- Management of lower urinary tract dysfunction 
The National Institute for Health Care and Excellence (NICE) guidelines state that PwMS and 
recurrent UTIs should be assessed by specialists for risk factors and offered appropriate 
treatment and guidance [7]. The occurrence of recurrent UTIs in PwMS may indicate 
suboptimal management of underlying LUT dysfunction, e.g. high bladder pressure during 
storage and voiding and incomplete bladder emptying.  
Different options are available to treat overactive bladder in MS patients, including oral 
antimuscarinic agents, tibial nerve stimulation, intradetrusor botulinum toxin A injections and 
sacral neuromodulation [1],[20]. Intradetrusor botulinum toxin A injections are highly 
effective for the management of detrusor overactivity in MS [26] and in fact, treatment has 
been shown to reduce the incidence of symptomatic UTIs.  The reasons for this are uncertain, 
however the treatment is associated with an improvement in urodynamic parameters with an 
improved reservoir capacity at low pressure [27].  Ultrasonography of the bladder is regularly 
performed to search for contributing factors, such as bladder stones. The need for an 
indwelling catheter should be reviewed [8] and if required, the type of catheter used may be 
relevant as a hydrophilic catheter is associated with a lower rate of UTIs, at least in men [28].  
Long-term indwelling urethral catheter should be avoided because of a higher risk of UTIs, 
urethral complications, bladder stones and cancer, and rather the option of ISC or suprapubic 
catheter should be considered [16]. Strategies to minimise infection should be rigorously 
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followed including catheter insertion under antiseptic conditions, use of a closed catheter 
drainage systems with dependent drainage and  regular changes of long-term catheters before 
likely blockage.  Patients with a large bladder capacity low pressure bladder may be managed 
using a flip-flow valve attached to the catheter after assessing suitability, thus avoiding the 
closed drainage bag.  Often these measures are insufficient to prevent UTIs and more specific 
preventative strategies may be required. However, these strategies remain largely unvalidated 
with a lack of high grade recommendation in international guidelines.  
 
 
- Antibiotic prophylaxis 
 
Continuous antibiotic prophylaxis for 6-12 months has been shown to be effective in reducing 
the rate of UTI during prophylaxis when compared to placebo in women without neurological 
disease [29]. However their use in neurological patients with LUT dysfunction is uncertain. 
The use of oral antimicrobial prophylaxis for preventing UTIs in this group was not supported 
in a metaanalysis by Morton et al [30] and is currently not recommended by NICE [7]. The 
concern about using antimicrobial prophylaxis is the emerging global problem of 
antimicrobial resistance as a two-fold increase in resistant bacteria was reported with this 
approach [30].  The results of a recent observational prospective pilot study by Salomon et al 
[31]  however  suggests that a weekly oral cyclic antibiotic (WOCA) regimen to prevent UTIs 
is both safe and efficacious in adult spinal-cord injured patients with LUT dysfunction 
performing ISC. The WOCA regimen consists of alternate administration of two antibiotics 
once a week over a period of at least 2 years.   The antibiotics chosen were effective for 
preventing UTIs, with a dramatic reduction in the incidence of UTIs from 9.4 symptomatic 
infections per patient-year and 197 episodes of febrile UTI responsible requiring 45 
hospitalizations before intervention, to 1.8 symptomatic UTIs per patient-year, 19 episodes of 
febrile UTI and 7 hospitalizations afterwards. No severe adverse events and no new cases of 
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colonization with multidrug resistant bacteria were reported [31]. This regimen requires to be 
studied in PwMS. 
 
- Cranberry 
 
The use of cranberry for UTI prophylaxis in MS is an attractive  option, as it appears to be a 
safe and natural choice. However, there are a few studies that have evaluated cranberry in 
preventing UTIs and the results have been mixed.  A meta-analysis of randomized controlled 
trials including heterogenous populations (patients with neurogenic bladder, elderly, pregnant 
women, women with recurrent UTIs and children) found that cranberry could reduce the 
number of UTIs by two-fold [32] whereas  a Cochrane review of 24 studies, with a total of 
4,473 subjects, revealed that cranberry products were of no benefit compared to placebo in 
most populations [33], including spinal cord injured patients (14.3%).  
A recent multicentre, randomized, placebo-controlled, double-blind trial in MS using 
cranberry extract could not demonstrate a reduction in UTI occurrence  in 171 patients [33].  
Therefore, the use of cranberry extracts for preventing UTIs is not supported by high-level 
evidence, though in practice is widely used by PwMS. 
 
 
- D-Mannose 
 
D- Mannose is a natural food supplement and is thought to work in a similar fashion as 
cranberry. Indeed, D-mannose binds to FimH at the tip of type 1 fimbria of enteric bacteria. 
During bacterial colonization, FimH binds to carbohydrate-containing glycoprotein receptors 
on the epithelium of the urinary tract. D-mannose shares similarity in structure to these 
urothelial glycoprotein receptors and therefore acts by competitively inhibiting bacterial 
adherence to carbohydrate-containing glycoprotein receptors on the epithelium of the urinary 
tract. 
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In a randomized-controlled trial, [35] the daily intake of D-mannose powder 2 g for recurrent 
UTI prophylaxis in women without neurological disease was evaluated and  a 45 % relative 
risk reduction was reported, with results similar to the use of preventative nitrofurantoin. The 
use of D-Mannose in PwMS is currently being studied in an on-going study 
(ClinicalTrials.gov NCT02490046). 
 
 
- Other approaches 
 
A variety of approaches have been evaluated but without proven efficacy. Bladder irrigation 
and methenamine hippurate has been studied, however there is insufficient evidence to 
support its use [36],[37]. The inoculation of apathogenic E. coli strains into the bladder has 
shown promise in initial randomized controlled studies, however further studies are required 
before recommendations could be made [38]. 
 
 
Conclusion 
 
 
Urinary tract infections are a major concern for PwMS and pose a challenge to the treating 
physician.  Despite the significant impact that UTIs have, there is a dearth of studies around 
the diagnosis and management of UTIs.  This review provides an overview of the diagnosis, 
treatment and prevention of UTIs in people with MS.  Known facts are the usefulness of 
urinalysis using to exclude a UTI and the non-treatment of asymptomatic UTIs except in the 
context of an acute MS relapse. Several options exist for the treatment of recurrent UTIs in 
MS, however none has been validated. Further studies targeting this specific population 
suffering from UTIs are needed. 
 
Abbreviations 
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UTI: urinary tract infection 
MS: multiple sclerosis 
LUT: lower urinary tract 
ISC: intermittent self-catheterisation 
 
Figure 
 
Figure 1. Flowchart for the testing for UTIs in patients with multiple sclerosis 
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